Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
SL

NASDAQ · SLDB

Solid Biosciences Inc.

Healthcare · Biotechnology

$9.54

Down-$0.47 (-4.93%)

Updated Sep 11, 2026, 12:26 AM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
458.1M
P/E ratio
-3.32
Dividend yield
0.00%
52-week range
$6.00 – $11.45
Volume
646.35K
Avg. volume
1.15M

Price performance

SLDB price history

1M range · 19 trading sessions · Daily adjusted prices

SLDB closed at $9.54 after 19 trading sessions, up 5.07% for the selected period.

Last close
$9.54
Period change
+5.07%
Period low
$9.08
Period high
$10.42
Daily close
View OHLC price history
SLDB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$9.77$9.95$9.53$9.54646.35K
Sep 8, 2026$10.00$10.09$9.58$9.93742.82K
Sep 4, 2026$10.20$10.48$10.20$10.25495.33K
Sep 3, 2026$10.30$10.46$10.05$10.42728.48K
Sep 2, 2026$9.92$10.435$9.75$10.285894.27K
Sep 1, 2026$9.44$9.95$9.37$9.88803.31K
Aug 31, 2026$9.73$9.73$9.37$9.58686.62K
Aug 28, 2026$10.02$10.095$9.72$9.77621.52K
Aug 27, 2026$10.03$10.27$9.89$10.13988.93K
Aug 26, 2026$9.84$9.85$9.60$9.72594.17K
Aug 25, 2026$9.33$9.90$9.33$9.891.26M
Aug 24, 2026$9.28$9.28$8.8604$9.161.11M
Aug 21, 2026$9.34$9.665$9.23$9.30790.37K
Aug 20, 2026$9.51$9.57$8.81$9.101.08M
Aug 19, 2026$9.42$9.87$9.2869$9.741.24M
Aug 18, 2026$8.99$9.14$8.84$9.08536.33K
Aug 17, 2026$9.05$9.16$8.90$9.10694.17K
Aug 14, 2026$9.09$9.345$8.73$9.20759.4K
Aug 13, 2026$9.14$9.26$8.93$9.08828.26K

Latest SLDB news

The latest Smart Investors Daily articles mentioning SLDB.

Stock researchCompany · Overview

SLDB research

Overview

Company profile and research snapshot.

Company profile

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.67
Implied upside
—
Analysts
19
SLDB recent ratings
DateFirmRatingTarget
Aug 27, 2026Cantor FitzgeraldOverweight—
Aug 21, 2026Truist SecuritiesBuy—
Jun 3, 2026HC Wainwright & Co.Buy—
May 18, 2026WedbushOutperform—
May 13, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare ConferenceBo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A li

Benzinga · Aug 27, 2026

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By